Athenex (ATNX) PT Lowered to $13 at Laidlaw, Following FDA CRL, Earnings
- S&P 500, Dow hit record highs on bank earnings boost
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar slips to 4-week low hurt by recent retreat in yields
- J&J (JNJ) Privately Asked Rival Covid-19 Vaccine Makers to Inspect Clotting Risks, AstraZeneca (AZN) Said Yes but Pfizer (PFE) and Moderna (MRNA) Declined - Report
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Laidlaw analyst Yale Jen lowered the price target on Athenex (NASDAQ: ATNX) to $13.00 (from $38.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Renewable Energy Group, Athenex, Ontrak, and Leidos and Encourages Investors to Contact the Firm
- Origin Energy Ltd. (ORG:AU) (OGFGY) PT Lowered to AUD6.50 at Goldman Sachs
- Saipem (SPM:IM) (SAPMY) PT Raised to EUR2.28 at Morgan Stanley
Create E-mail Alert Related CategoriesAnalyst PT Change
Related EntitiesEarnings, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!